BioNetwork 2017

October 23-October 25, 2017

The Ritz-Carlton, Laguna Niguel, CA

1.888.482.6012

Day 2: Tuesday, October 24, 2017

07:45 AM - 08:45 AM Registration and Breakfast

08:45 AM - 08:50 AM Welcome Remarks

08:50 AM - 09:05 AM Chairperson's Opening Remarks


img

James Bowen

Executive Director, Corporate Alliances
University of Pennsylvania
img

Dave Greenwald

Director of Business Development
Johns Hopkins Technology Ventures
img

Alan Jakimo

Director
The Cancer Trust
img

Lisa Placanica

Director, Business Development
Mount Sinai Innovation Partners
img

Samy Tadros

Senior Director, Business Development and Global Alliances
Celgene
img

Ofra Weinberger

Director of Licensing
Columbia Technology Ventures

09:35 AM - 10:05 AM Biotech Spotlights

With a series of innovations that is unprecedented, some key questions arise for immunotherapy partnering:
What are the partnering challenges and opportunities in combination immuno-oncology therapy?
Is there opportunity to advance pricing and what are the legal and commercial aspects?
How do you successfully agree on pricing innovation?

img

Nouhad Husseini

VP, Business Development
Regeneron
img

Prakash Raman

VP, Global Head of Oncology Business Development & Licensing
Novartis Oncology

1:1 Partnering

10:05 AM - 10:35 AM 1:1 Partnering

General Session

10:35 AM - 11:05 AM Morning Refreshment Break

1:1 Partnering

10:35 AM - 11:05 AM 1:1 Partnering

  • What are the advantages of having corporate VCs in your capital structure?
  • What are the benefits of a big pharma company having a venture arm?
  • Are there differing approaches in looking for opportunities between corporate and traditional VCs?

img

Rajeev Dadoo

Partner
SR One
img

Marianne De Backer

Vice President, Venture Investments
Johnson & Johnson Innovation
img

Markus Goebel

Managing Director
Novartis Venture Fund
img

Elaine Jones

VP, Venture Capital
Pfizer

Michael Martin

President
Takeda Ventures
img

Michael O'Donnell

Partner
Morrison Foerster

1:1 Partnering

11:05 AM - 11:45 AM 1:1 Partnering


img

Sia Anagnostou

Senior Director, Corporate Development
Immunomic Therapeutics, Inc.

1:1 Partnering

11:45 AM - 12:30 PM 1:1 Partnering

12:30 PM - 1:30 PM Luncheon

1:30 PM - 2:00 PM Biotech Spotlights

What are the key challenges in conducting diligence?
What do you perceive to be the key challenges?
What approaches are most effective in getting validated insights faster?

img

Younes Bekkali

Director, Business Development & Licensing - Strategic Transactions
Boehringer Ingelheim
img

Scott Goedeke

President
Viscadia
img

Lesley Stolz

Senior Director, Transactions
Johnson & Johnson Innovation
img

Jeffrey Warmke

SVP, External Scientific Affairs
Daiichi Sankyo
img

Joe Whalen

SVP, Business Development & Alliance Management
Horizon

1:1 Partnering

2:00 PM - 2:30 PM 1:1 Partnering

What are the latest developments in the emerging model of companies started by VCs?
What is the current appetite for risk across the biopharma venture community?
How do strategies differ from large VC to new venture funds?

img

Neena Kadaba

Director, Science
Quark Venture
img

Debbie Liebert

Managing Director
Domain Associates
img

Julie Papanek

Partner
Canaan Partners

1:1 Partnering

2:30 PM - 3:00 PM 1:1 Partnering

General Session

3:00 PM - 3:30 PM Afternoon Refreshment Break

1:1 Partnering

3:00 PM - 3:30 PM 1:1 Partnering

General Session

3:30 PM - 4:30 PM Biotech Spotlights

1:1 Partnering

3:30 PM - 4:30 PM 1:1 Partnering

Looking back on the past year, what are the creative, high-profile deals?
What are unconventional approaches that have proven successful?
How is biopharma collaboration evolving and what can we expect?

img

Lisa Beck

Executive Director, Transactions Global Business Development
Alexion
img

Damien McDevitt

VP & Head of BD for R&D Extended Therapy Areas
GlaxoSmithKline
img

Scott Shanuessy

CEO
ideaPoint
img

Alex Szidon

AVP, Business Development & Licensing
Merck

1:1 Partnering

4:30 PM - 5:00 PM 1:1 Partnering

5:00 PM - 6:00 PM Monte Carlo Casino Night

6:00 PM - 11:59 PM End of Day Two